Protocol
Low-energy formula diet for type 2 diabetes remission
This record grades a supervised program, not a food or a product: about 800 to 850 kcal a day of formula meal replacements for roughly 12 to 20 weeks, a stepped return to food, and structured support to keep the weight off, given to adults with type 2 diabetes of a few years' standing and overweight or obesity.
At a glance
This page is about a diet program for type 2 diabetes, not a product. For three to five months, meals are replaced by shakes and soups of about 800 calories a day. Then normal food comes back step by step, with help to keep the weight off. In a UK trial, almost half the people in the program no longer had diabetes after a year. They were off their diabetes drugs. Under usual care, 1 in 25 did. A team in Qatar found much the same in younger adults. The gain shrank as weight came back. No trial has tested this program against heart attacks or deaths.
- What was measured
- Whether type 2 diabetes was in remission after 12 months: a long-term blood sugar test (HbA1c A blood test that reflects average blood sugar over the previous two to three months.) below 6.5% with all diabetes drugs stopped.
- How big
- 46% of the program group were in remission after a year, against 4% under usual care.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 29221645.
- Who it applies to
- Adults aged 20 to 65 with type 2 diabetes diagnosed within 6 years and overweight or obesity, not on insulin; an independent trial in younger adults in Qatar agrees.
- Safety
- Diabetes and blood pressure drugs were stopped by the clinical team at the start; two serious events in one participant, biliary colic and abdominal pain, were judged possibly related.
- Compared with
- Best-practice diabetes care from the same kind of family doctor practices.
- Certainty
- Grade B, resting on: Randomized controlled trials People are assigned to the treatment or a comparison by chance, so the groups differ only in what they received. It is the design that can show cause and effect. (DiRECT, DIADEM-I) with a 5-year follow-up.
- What would change this grade
- Could rise to A with: Randomized trial of a low-energy formula diet program against usual care in type 2 diabetes, with events adjudicated blind to group. Who: Adults with type 2 diabetes and overweight or obesity, at least 2,000 per arm. Measured: Heart attack, stroke, kidney failure and death. Length: At least 5 years.
- Cost
- No price recorded yet.
- Sources
- 5 studies cited on this record, listed under Sources.
- For clinicians
- A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
Remission of type 2 diabetes (HbA1c below 6.5% off all glucose-lowering drugs) at 12 months against usual care, adults with type 2 diabetes diagnosed within about 3 to 6 years and overweight or obesity, not on insulin.
Why this letter
Why this gradeThe reasoning, and what the grade does not cover.
Grade B on remission of type 2 diabetes. DiRECT randomized 49 UK practices and found remission, HbA1c below 6.5% off all glucose-lowering drugs, in 46% of the program group against 4% at 12 months (Lean 2018, PMID 29221645) and 36% against 3% at 24 months (Lean 2019, PMID 30852132). An independent group in Qatar found 61% against 12% at 12 months in younger adults (DIADEM-I, Taheri 2020, PMID 32445735). Two randomized trials from independent groups agree on an endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. defined by HbA1c, which the B definition names as an established stand-in.
WHY NOT AHbA1c is a surrogate, and no trial of this program has measured heart attacks, strokes, kidney failure or deaths; Look AHEAD, a less intensive lifestyle program in type 2 diabetes, found no fewer cardiovascular events (Wing 2013, PMID 23796131).
WHAT THIS GRADE DOES NOT COVERpeople on insulin or with diabetes of many years, who were not enrolled; remission beyond 2 years, which fell to 13% of those still followed at 5 years (PMID 38423026); and any single meal replacement product.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Trials report an average. This box says whether any trial on this record looked at who the result applies to, and what it found.
For this record's Grade B · Subgroup tested, effect differedIn DiRECT remission rose with weight lost across the whole study population: none of 76 who gained weight, 7% of those who lost up to 5 kg, 34% at 5 to 10 kg, 57% at 10 to 15 kg and 86% of those who lost 15 kg or more (Lean et al., Lancet, 2018; PMID 29221645). A subgroup result shows who the effect appeared in within these trials. It does not change the letter. This subgroup was identified after the results were in and has not been confirmed in a trial designed to test it.
Evidence notes: randomized trial
Endpoint graded: Type 2 diabetes remission at 12 months: HbA1c below 6.5% with all glucose-lowering drugs stopped (surrogate)
Last reviewed: November 2026
The trial that would change this grade.
Positive trials of this shape from independent research groups would move this entry to A.
Why the current trials fall short
The B rests on remission defined by HbA1c, an established stand-in, in two independent randomized trials. A replicated The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. reduction in hard outcomes would raise it; Look AHEAD (PMID 23796131), a less intensive lifestyle program, found none.
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Type 2 Diabetes Remission among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Search recruiting studies of Type 2 Diabetes Remission on ClinicalTrials.gov
Dose, form and timing
Measured outcomes in the graded trials: HbA1c off all glucose-lowering drugs at 12 and 24 months (PMIDs 29221645, 30852132) and at 12 months (PMID 32445735), with body weight. In DiRECT remission rose with the weight lost and was reached by 86% of those who lost 15 kg or more (PMID 29221645).
As studiedDose, form, population and duration for every use.
A grade describes the intervention that was tested. Where the product on the shelf differs from it, this says so.
Safety
In DiRECT, glucose-lowering and blood pressure drugs were stopped by the clinical team on the first day of the diet, and the trials did not enroll people on insulin. Two serious adverse events in one participant in the program group, biliary colic and abdominal pain, were judged possibly related to the program (Lean 2018, PMID 29221645).
No safety data. Each caution on this record, sorted by what it rests on.
None recorded.
None recorded.
None recorded.
None recorded.
No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.
Grade history
How this letter has changedLatest: No. 451 · November 2026 · First graded.
A supervised program of about 800 kcal a day of formula meals, a stepped return to food and support to keep the weight off now has its own record. In DiRECT, 46% of the program group were in remission at 12 months, HbA1c below 6.5% with all diabetes drugs stopped, against 4% under usual care: Lean et al. (Lancet, 2018; PMID 29221645). An independent trial in Qatar found 61% against 12%: Taheri et al. (Lancet Diabetes Endocrinol, 2020; PMID 32445735). Grade B, because remission is defined by HbA1c, an established stand-in; no trial of the program has measured heart attacks, strokes or deaths.PMID 29221645 PMID 32445735
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- November 2026. By the EBL editor, Arnold Sandlow, DC.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
The evidence, in fullFive papers, each linked to its PubMed record.
Lean et al. (Lancet, 2018; PMID 29221645): DiRECT, open-label Everyone in the trial knows which treatment they are receiving, so expectations can shape the results, especially for symptoms people report themselves. cluster-randomized trial in 49 primary care practices in Scotland and Tyneside; 306 adults aged 20 to 65, diagnosed within 6 years, BMI 27 to 45, not on insulin; glucose-lowering and blood pressure drugs were withdrawn at the start, then 825 to 853 kcal a day of formula diet for 3 to 5 months, stepped food reintroduction over 2 to 8 weeks, and structured maintenance support; at 12 months remission in 68 of 149 (46%) against 6 of 149 (4%) under best-practice care, weight 10.0 kg lower against 1.0 kg. Lean et al. (Lancet Diabetes Endocrinol, 2019; PMID 30852132): the same trial at 24 months, remission in 53 of 149 (36%) against 5 of 149 (3%). Lean et al. (Lancet Diabetes Endocrinol, 2024; PMID 38423026): 5-year extension, an observational follow-up after the randomized period; original program participants had more visits in remission than controls (27% against 4%), and 26% of those in remission at 2 years were still in remission at 5 years. Taheri et al. (Lancet Diabetes Endocrinol, 2020; PMID 32445735): DIADEM-I, open-label randomized trial in primary care and community settings in Qatar; 158 adults aged 18 to 50 from the Middle East and North Africa, diabetes of 3 years or less, BMI 27 or more; low-energy formula meal replacement then gradual food reintroduction with physical activity support; weight at 12 months, the primary outcome, 11.98 kg lower against 3.98 kg; remission, a key secondary outcome, 61% against 12%. Wing et al. (N Engl J Med, 2013; PMID 23796131): Look AHEAD, 5,145 adults with type 2 diabetes and overweight or obesity randomized to an intensive lifestyle program for weight loss or diabetes support and education; stopped for futility at a median 9.6 years with no difference in cardiovascular death, heart attack, stroke or hospitalization for angina (hazard ratio How often an event happened in the treated group compared with the control group over the same period. A ratio of 0.80 means 20 percent fewer events. 0.95). It tested a different, less intensive program and is cited for the hard-outcome question only. Funding: DiRECT was funded by Diabetes UK and the formula diet was donated by its maker, which then owned the company whose program the trial delivered; the trial's senior investigators developed that program. DIADEM-I was funded by the Qatar National Research Fund, used a commercially available meal replacement plan given to participants free of charge, and its authors declared no competing interests.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
("low energy diet"[tiab] OR "low-energy diet"[tiab] OR "total diet replacement"[tiab] OR "very low calorie"[tiab] OR "meal replacement"[tiab]) AND "type 2 diabetes"[tiab] AND remission[tiab] AND (randomized controlled trial[pt] OR randomized[ti] OR randomized[ti])PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the searches behind this grade has been added to PubMed since November 2026.
Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.
- Lean et al., 2018, Lancet (PMID 29221645): PubMed lists funding from Diabetes UK; Department of Health; Medical Research Council.
- Lean et al., 2019, Lancet Diabetes Endocrinol (PMID 30852132): PubMed lists funding from Diabetes UK; Medical Research Council; Department of Health.
- Lean et al., 2024, Lancet Diabetes Endocrinol (PMID 38423026): PubMed lists funding from Diabetes UK. The PubMed record carries a competing-interest statement.
- Taheri et al., 2020, Lancet Diabetes Endocrinol (PMID 32445735): PubMed lists funding from Qatar National Research Fund.
- Look AHEAD Research Group, 2013, N Engl J Med (PMID 23796131): PubMed lists funding from National Institutes of Health and others; US National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases); US National Institutes of Health (National Center for Advancing Translational Sciences); US National Institutes of Health (National Center for Research Resources); US National Institutes of Health (National Heart, Lung, and Blood Institute); US National Institutes of Health.
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →